Overview

This book's focus is on Alzheimer's, the many additional diseases that cause dementia and the reasons for the lack of drugs to treat these neurological dysfunctions. Suggested changes to the USA's Food and Drug Administration (FDA) protocols are offered in order to accelerate the drug development pipeline and reduce the huge costs required to conduct human clinical trials. The importance of the brain renin-angiotensin system is described and possible new directions in drug development are discussed, along with the changing role of academic researchers in identifying and developing new treatment strategies. The book was written for those families touched by Alzheimer's and other dementias, academic scientists interested in neurodegenerative diseases, and would-be entrepreneurs considering beginning a start-up company.

Full Product Details

9781036406059

Table of Contents

Reviews

Author Information

John (Jay) W. Wright, PhD, is a retired professor who taught psychology, neuroscience and biotechnology at Washington State University, USA, for 39 years and has authored more than 200 peer reviewed journal articles, reviews and chapters. Jay is an internationally recognized expert on the role of neuropeptides in the control of memory, blood pressure, synaptogenesis and neurogenesis. He is the co-inventor, with Dr Joseph Harding, of more than a dozen nationally and internationally issued patents. He also co-founded Athira Pharma, Inc., located in Seattle, USA, which focuses on completing clinical trials with the first-in-class drug Fosgo, administered to Alzheimer's and amyotrophic lateral sclerosis (ALS) disease patents.

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available